<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413647</url>
  </required_header>
  <id_info>
    <org_study_id>CardioPET P-01</org_study_id>
    <nct_id>NCT00413647</nct_id>
  </id_info>
  <brief_title>A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of CardioPET™ as a PET Tracer for Detection of Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fluoropharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fluoropharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and dosimetry of CardioPET™ will be evaluated in normal healthy volunteers and CAD&#xD;
      subjects both male and female between the ages of 50-85. Nine normal controls will undergo&#xD;
      repeated whole body imaging for biodistribution and dosimetry estimation. Six other normal&#xD;
      healthy subjects will undergo heart imaging only. Six CAD subjects will undergo heart imaging&#xD;
      only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CardioPET™ is a modified fatty acid (MFA) that closely resembles naturally-occurring free&#xD;
      fatty acids (FFAs) in the human body.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      Visit 1: Screening - Eligibility determination&#xD;
&#xD;
      Visit 2: Injection and PET Imaging&#xD;
&#xD;
      Visit 3: Follow-up Visit&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vital signs. Change in physical examination. Change in ECG. Change in 24-hour Holter. Change in dosimetry (blood and urine)measured at time 0 (immediately folloing injection), 1, 5, 15, 30, 60, and 90 minutes. Adverse event assessment.</measure>
    <time_frame>Screening, Pre-dose, Baseline, Day 1, Pre-, Post-Dose 0, 24-48 hours and 7 days (Adverse events).</time_frame>
    <description>Normal healthy volunteers for whole body imaging group and NHV and Coronary Artery Disease (CAD)undergoing cardiac imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance characteristics of CardioPET as a PET tracer for myocardial imaging.</measure>
    <time_frame>0, 1 min, 5 min, 15 min, 30 min, 60 min, and 90 min.</time_frame>
    <description>Normal healthy volunteers and CAD subjects for Cardiac Imaging Only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation and optimization of the methods of image acquisition, output processing, display, reconstruction, and imaging data</measure>
    <time_frame>Baseline, 15 second time frames for first 2 minutes, 1 min. time frame for next 8 min., 2 min frames for remainder of 60 min study.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CardioPET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CardioPET</intervention_name>
    <arm_group_label>CardioPET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Normal Healthy Volunteers:&#xD;
&#xD;
          -  Subject must provide written informed consent prior to any study related procedures&#xD;
&#xD;
          -  Subjects must be between the ages of 50 and 85 years of age.&#xD;
&#xD;
        Coronary Artery Disease (CAD) subjects:&#xD;
&#xD;
          -  Subjects must provide written informed consent prior to any study related procedures;&#xD;
&#xD;
          -  Subjects must be ≥ 50 and ≤ 85 years of age;&#xD;
&#xD;
          -  Subject must have history of CAD documented by an exercise stress Myocardial Perfusion&#xD;
             Imaging (MPI) study within 6 months documenting myocardial infarct without ischemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Normal Healthy Volunteers:&#xD;
&#xD;
          -  Any clinically significant acute or unstable physical or psychological disease based&#xD;
             on medical history or screening physical examination&#xD;
&#xD;
          -  Any clinically significant abnormality in the screening laboratory tests or ECG&#xD;
&#xD;
          -  Fasting blood glucose level over 120 mg/dl&#xD;
&#xD;
          -  Any exposure to any investigational drugs with four(4)weeks prior to Visit 1&#xD;
&#xD;
          -  Any exposure to radiopharmaceuticals within four(4)weeks prior to the date of Visit 1&#xD;
&#xD;
          -  Any new prescription medications within four(4)weeks of Visit 1&#xD;
&#xD;
          -  Subject has a Positive(+)Serum and/or Urine Pregnancy Test or is lactating, or the&#xD;
             possibility of pregnancy cannot be ruled out prior to dosing. There are standard&#xD;
             pregnancy procedures for use of radiopharmaceuticals in research at MGH&#xD;
&#xD;
        Coronary Artery Disease (CAD) Subjects:&#xD;
&#xD;
          -  Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the&#xD;
             possibility of pregnancy cannot be ruled out prior to dosing;&#xD;
&#xD;
          -  Any clinically significant acute or unstable physical or psychological disease judged&#xD;
             by the investigators based on medical history or screening physical examination;&#xD;
&#xD;
          -  Coronary artery bypass graft (CABG) within 1 year;&#xD;
&#xD;
          -  Percutaneous coronary intervention (PCI), with stent placement within three months;&#xD;
&#xD;
          -  Blood pressure over 180/100;&#xD;
&#xD;
          -  Acute changes in ECG;&#xD;
&#xD;
          -  Cardiac ischemia identified by MPI stress test;&#xD;
&#xD;
          -  Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction,&#xD;
             cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical&#xD;
             procedures;&#xD;
&#xD;
          -  Any implanted pacemaker or defibrillator use within the last three months;&#xD;
&#xD;
          -  Inability to remain in camera for approximately 60 minutes (Smokers and COPD are&#xD;
             included as long as they can breath in PET camera and not taking O2 through nasal&#xD;
             canola);&#xD;
&#xD;
          -  History of Diabetes Mellitus;&#xD;
&#xD;
          -  Serum creatinine &gt; 2 mg/dL;&#xD;
&#xD;
          -  All cancer and or chemotherapy patients;&#xD;
&#xD;
          -  Body Mass Index (BMI) is over 35;&#xD;
&#xD;
          -  Any exposure to any investigational drugs or medical device within four (4) weeks&#xD;
             prior to imaging study;&#xD;
&#xD;
          -  Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of&#xD;
             imaging study;&#xD;
&#xD;
          -  High daily alcohol consumption over 4 alcohol drinks per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J. Fischman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>December 18, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CardioPET</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>Radiation Dosimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

